A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity

Annals of Oncology

Volumn 18, Issue 4, 2007, Pages 768-774

  Mok, T S K ^a   Yeo, W ^a   Johnson, P J ^b   Hui, P ^a   Ho, W M ^a   Lam, K C ^a   Xu, M ^c   Chak, K ^a   Chan, A ^a   Wong, H ^a   Mo, F ^a   Zee, B ^a,d  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alternative and complementary medicine; Chemotherapy; Chinese herbal medicine; Colonic neoplasms; Emesis; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; BLACK BEAN EXTRACT; CHINESE DRUG; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GRANISETRON; HERBACEOUS AGENT; MALTOSE; METOCLOPRAMIDE; PLACEBO; PLANT EXTRACT; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHINESE MEDICINE; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG GRANULE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MANUFACTURE; DRUG TOXICITY; EARLY CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HERBAL MEDICINE; HUMAN; INCIDENCE; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ODOR; PAIN; PATIENT COMPLIANCE; PIGMENT DISORDER; POSTOPERATIVE CARE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; TEA; THROMBOCYTOPENIA;

EID: 34047111338     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl465     Document Type: Article

References (18)

1. Sparber A, Wootton JC. Surveys of complementary and alternative medicine: Part II. Use of alternative and complementary cancer therapies. J Altern Complement Med 2001; 7: 281-287.
2. DiGianni LM, Garber JE, Winer EP. Complementary and alternative medicine use among women with breast cancer. J Clin Oncol 2002; 20 (18 Suppl): 34S-38S.
3. Boon H, Stewart M, Kennard MA et al. Use of complementary/alternative medicine by breast cancer survivors in Ontario: Prevalence and perceptions. J Clin Oncol 2000; 18: 2515-2521.
4. Ashikage T, Bosompra K, O'Brien P et al. Use of complimentary and alternative medicine by breast cancer patients: Prevalence, patterns and communication with physicians. Support Care Cancer 2002; 10: 572-578.
5. Richardson MA, Sanders T, Palmer JL et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000; 18 (13): 2505-2514.
6. Ng TP, Tan CH, Kua EH. The use of Chinese herbal medicines and their correlates in Chinese older adults: The Singapore Chinese Longitudinal Aging Study. Age Ageing 2004; 33 (2): 135-142.
7. Cui Y, Shu XO, Gao YT et al. Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Res Treat 2004; 85: 263-270.
8. Eisenberg DM, Davis RB, Ettner SL et al. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 1998; 280:1569-1575.
9. Lu AP, Jia HW, Cheng X et al. Theory of traditional Chinese medicine and therapeutic method of diseases. World J Gastroenterol 2004; 10 (13): 1854-1856.
10. Yamamoto K, Hoshiai H, Noda K. Effects of Shakuyaku-kanzo-to on muscle pain from combination chemotherapy with paclitaxel and carboplatin. Gynecol Oncol 2001; 81 (2): 333-334.
11. Mori K, Kondo T, Kamiyama Y et al. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2003; 51: 403-406.
12. Dixon JR Jr. The International Conference on Harmonization Good Clinical Practice Guideline. Qual Assur 1998; 6 (2): 65-74.
13. Ang PT, Buzdar AU, Smith TL, Kau S et al. Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcnioma. J Clin Oncol 1989; 7: 1677-1684.
14. Shukla Y, Taneja P. Anticarcinogenic effect of black tea on pulmonary tumor in Swiss albino mice. Cancer Lett 2002; 176 (2): 137-141.
15. Halder A, Raychowdhury R, Ghosh A, De M. Black tea (Camellia sinensis) as a chemopreventive agent in oral precancerous lesions. J Environ Pathol Toxicol Oncol 2005; 24 (2): 141-144.
16. Aaronson NK, Ahmedzai S, Bergman B. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85 (5): 365-376.
17. Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res 2000; 9 (2): 129-137.
18. Bensoussan A, Talley N, Hing M et al. Treatment of irritable bowel syndrome with Chinese herbal medicine. JAMA 1998; 280 (18): 1585-1589.